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 Immunosuppression is a major complication of alcoholism and contributes to increased 
rates of opportunistic infections and sepsis associated with the addiction. The NLRP3 
inflammasome is a central intracellular pattern recognition receptor within the innate immune 
system, which leads to the cleavage and secretion of the pro-inflammatory cytokines interleukin 
(IL)-1β and IL-18. Ethanol has been reported to inhibit IL-1β secretion, and here we verify that 
the alcohol can specifically inhibit activation of the NLRP3 inflammasome resulting in 
attenuated IL-1β and caspase-1 cleavage and secretion, as well as ASC secretion in response to 
several agonists. These results were found to be independent of the activation of GABAA 
receptors or the inhibition of NMDA receptors. Ethanol was only partially able to prevent IL-1β 
secretion subsequent to NLRC4 activation and was incapable of preventing NLRP1b dependent 
IL-1β secretion, which are both largely independent of the adapter protein ASC, and ethanol was 
shown to prevent the formation of ASC specks. Treatment of cells with ethanol resulted in 
markedly decreased global tyrosine phosphorylation, while administration of the tyrosine 
phosphatase inhibitor sodium orthovanadate prior to ethanol restored IL-1β secretion. Multiple 
alcohol containing organic compounds exerted inhibitory effects on the NLRP3 inflammasome 
parallel to ethanol; however, isoamyl alcohol’s non-alcohol analog, 2-methylbutane, did not. 
Together, these results show that ethanol antagonizes the NLRP3 inflammasome at an apical 
event in its activation potentially through the stimulation of protein tyrosine phosphatases. As 
other short chain alcohols retain this ability, this effect could be dependent on the hydroxyl group 





 Inflammasomes are a family of large multi-protein intracellular pattern recognition 
receptors (PRRs) that respond to a wide variety of exogenous pathogen associated molecular 
patterns (PAMPs) and endogenous danger associated molecular patterns (DAMPs), facilitating 
the secretion of the pro-inflammatory cytokines, IL-1β and IL-18, as well as a form of 
inflammatory cell death known as pyroptosis (1). Unlike many innate immune pathways, 
stimulation of a functional inflammasome requires two steps. During priming (step 1), activation 
of the transcription factor NF-κB, downstream of the stimulation of many PRRs, leads to the 
production of several components of the inflammasome and the secretion of the pro-
inflammatory cytokine TNFα (2). Activation of the inflammasome (step 2) requires the exposure 
of cells to a separate set of PAMPs and DAMPs, which work through unique signaling pathways 
leading to the oligomerization of one of several different Nucleotide Oligomerization Domain 
(NOD)-Like Receptor (NLR) proteins, the adaptor protein Apoptosis-associated Speck-like 
protein containing a CARD (ASC), and pro-caspase-1 into an organized inflammasome complex 
(3). This oligomerization is mediated by homotypic PYRIN-PYRIN domain binding between 
NLRs and ASC, and CARD-CARD interactions between ASC and pro-caspase-1, resulting in 
the formation of a discrete ASC speck within stimulated cells (4). These ASC specks form 
rapidly and irreversibly within activated cells and are a platform for efficient pro-IL-1β and pro-
IL-18 cleavage. While the activity of all inflammasomes is thought to be enhanced by the 
incorporation of ASC into their complexes, NLRP1 and NLRC4 contain their own CARD 
domains and can interact directly with pro-caspase-1 independent of ASC (5). This assembly 
allows for the conversion of pro-caspase-1 into an active caspase-1 enzyme, which cleaves pro-
IL-1β and pro-IL-18 into their mature, secreted forms. These cytokines then function to promote 
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vasodilation, attract and stimulate neutrophils, induce fever, and activate the acute phase 
response within an organism (6). Some consider the secretion of IL-1β and IL-18 to be a third 
step in the process of inflammasome activation. Both IL-1β and IL-18 are leaderless proteins, 
which despite years of research and many proposed models, still do not have a well-defined 
mode of release (7). The final outcome of inflammasome formation, pyroptotic cell death, is 
believed to amplify the immune response while depleting pathogens of their host leukocyte niche 
(8). 
 The NLRP3 inflammasome is capable of responding to a particularly diverse set of 
PAMPs and DAMPs, including ATP, nigericin, alum, asbestos, silica, and cholesterol crystals 
(9-13). These agonists activate the inflammasome through disparate pathways, such as K
+
 efflux 
and lysosomal rupture, eventually converging on ASC phosphorylation and multimerization (14, 
15). As a result, this inflammasome, expressed predominantly by macrophages, but also 
monocytes, neutrophils, dendritic cells, some lymphocytes, and cells that are not leukocytes, 
plays a major function in immune homeostasis (16). Beyond its protective roles in response to 
pathogens, over-activation of the NLRP3 inflammasome has been implicated in the pathogenesis 
of an array of diseases such as atherosclerosis, diabetes, gout, and multiple sclerosis (17-19). 
Similarly, gain of function mutations in NLRP3 lead to the set of debilitating diseases known as 
Cryopyrin-Associated Periodic Syndrome (CAPS) (20). Although many inhibitors of signal 1 are 
known, until recently few compounds capable of directly inhibiting signal 2 were discovered. 
Alcohol use disorders were estimated to be the third most common non-genetic cause of 
mortality in the U.S. in the year 2000 (21). Alcohol abuse predisposes individuals to 
opportunistic infections and organ damage, which are the two most prominent alcohol-related 
medical complications (21). In trauma and post-surgical patients, alcohol exposure occurring 
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prior to or at the time of injury enhances morbidity and mortality due to increased rates of sepsis 
and shock, and chronic alcoholics account for 50% of all Acute Respiratory Distress Syndrome 
patients (22, 23). Furthermore, light to moderate alcohol consumption is associated with 
decreased risks of developing coronary artery disease and atherosclerosis, illnesses commonly 
associated with systemic inflammation (17). The pattern of drinking differentially affects the 
consequences of alcohol abuse. Binge alcohol consumption suppresses host innate immune 
defense, while chronic alcohol consumption suppresses innate and adaptive immune systems, yet 
activates chronic inflammation (24). 
Ethanol is a known inhibitor of signal 1 (the consequences of PRR signaling) and its 
consumption is associated with decreased circulating levels of TNFα and IL-1β (25, 26). 
Recently, ethanol, but not its metabolite acetaldehyde, was found to also be capable of inhibiting 
signal 2 for the NLRP3 and AIM2 inflammasomes (17). The methods through which ethanol 
exerts its immunosuppressive effects are still unclear, yet given the central role that 
inflammasomes play in the immune response, it is possible that direct inhibition of signal 2 could 
be an important target of alcohol induced immunosuppression. 
Ethanol is known to have a wide range of effects when administered to cells. At high 
doses, it can alter membrane fluidity and can diffuse across the plasma membrane to interact 
with cytosolic proteins (27). Some known intracellular effects of acute ethanol administration 
include tyrosine phosphatase and adenylyl cyclase activation (28, 29). At lower doses, ethanol is 
thought to interact with a variety of cell surface receptors, particularly neurotransmitter 
receptors, in an agonistic or antagonistic manner (30, 31). During chronic exposure to ethanol, 
gene expression can be altered, potentially contributing to the differences that chronic alcoholism 
and binge drinking exert on immune function (32). 
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The goal of this study was to further elucidate the mechanism of ethanol’s inhibition of 
the NLRP3 inflammasome, primarily using the J774 mouse macrophage and THP-1 human 
monocyte cell lines and a protocol resembling binge drinking in humans. Experiments were 
designed to assess ethanol’s ability to directly inhibit signal 2, rather than its already well-
defined capacity to prevent NF-κB and signal 1 activation. By identifying pathways involved in 
ethanol’s blockade of this key innate immune complex, we hope to better understand and 
determine potential sites of therapeutic intervention in ethanol mediated immunosuppression and 
also to identify potential targets for future NLRP3 inflammasome inhibitors. 
 
Materials and Methods 
Reagents 
 LPS, isoamyl alcohol, 2-methylbutane, picrotoxin, 3-(2-Carboxypiperazin-4-yl)propyl-1-
phosphonic acid, and monoclonal anti-mouse β-actin antibodies were all purchased from Sigma-
Aldrich (St. Louis, MO). ASC and caspase-1 antibodies were purchased from Santa Cruz 
Biotechnology Inc. (Dallas, TX), anti-phosphotyrosine antibodies from Cell Signaling (Danvers, 
MA), and anti-mouse IL-1β antibodies from R&D Systems (Minneapolis, MN). Recombinant 
mature mouse IL-1β was also purchased from R&D Systems. Biotin conjugated anti- mouse and 
rabbit secondary antibodies were from GE Healthcare UK Limited (Little Chalfont, 
Buckinghamshire) and anti-goat IgG from Jackson ImmunoResearch (West Grove, PA). For 
inflammasome stimulation, ATP, nigericin, alum Imject, alum powder, apoSAA, and anthrax  
lethal factor and protective antigen were purchased from Amersham Biosciences (Piscatawy, 
NJ), Invivogen (San Diego, CA), Thermo Scientific (Waltham, MA), Natural Provisions Market 
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(Williston, VT), PeproTech Inc. (Rocky Hill, NJ) and BEI Resources (Manassas, VA) 
respectively. Muscimol was acquired from MP Biomedicals (Santa Ana, CA), and ethanol from 
Pharmco AAPER (Brookfield, CT). 
Cell Culture 
 J774 cells purchased from American Type Culture Collection (ATCC, Manassas, VA) 
were maintained in DMEM media (Gibco, Grand Island, NY) supplemented with 10% FBS 
(Gibco), 1% L-Glutamine (Gibco), and 1x Primocin (Invivogen, San Diego, CA). Cells were not 
used beyond passage 20 to reduce variability between the experiments. EGFP and ASC-EGFP 
stably transfected THP-1 cells were kindly gifted to us by Dr. Mark D. Wewers (Ohio State 
University) (33) and were maintained in RPMI medium (Gibco) supplemented with 10% FBS 
(Gibco), 1% L-Glutamine (Gibco), 1% Pen/Strep (Gibco), and 5µM β-ME (Sigma). 
For experiments in which cell supernatants were examined by ELISA, cells were plated 
at 2.5x10
5
 cells/well in a 48-well plate in 250μl of media and allowed to grow overnight. The 
following day, the media was removed, fresh media was added and cells were treated as 
indicated within the figure for each experiment. Cell supernatants were harvested at the end of 
each experiment, spun down at 6,000 rpm for 10 minutes to pellet cellular debris, transferred to 
new tubes, and frozen at -20˚C until analysis. 
For experiments analyzed through western blotting, J774 cells were plated at 3x10
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cells/well in 2ml of media in a 6-well plate and allowed to grow overnight. The next day, the 
media was removed, cells were washed twice in warm PBS and placed in serum free media. The 
cells were treated as indicated within each experiment’s figure. Supernatants were spun down at 
6,000 rpm, transferred to new tubes, and frozen at -20˚C. The cells were then washed twice with 
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PBS and lysed in RIPA buffer (50mM Tris pH 8, 150mM NaCl, 1% NP-40, 0.5% deoxycholate, 
0.1% SDS) containing 1mM sodium orthovanadate (Sigma-Aldrich), 1x protease cocktail 
inhibitor (Sigma-Aldrich), and 1x PMSF (Sigma-Aldrich) on ice for 10 minutes with scraping. 
Cellular debris was removed through centrifugation at 6,000 rpm for 10 minutes, the lysates were 
transferred to new tubes, and frozen at -20˚C. Before running on a gel, protein concentrations in 
the lysates were quantified by a detergent compatible protein assay. For all experiments using 
J774 cells the previously determined dose of LPS for half maximal IL-1β secretion, upon 
stimulation, was used (37ng/ml). 
For the visualization of ASC specks, ASC-EGFP and EGFP THP-1 cells were plated at 
2.5x10
5
 cells/well in 12-well plates and differentiated with PMA (Sigma-Aldrich) for 24 hours. 
The cells were then washed with PBS and placed in fresh media for an additional 48 hours. The 
THP-1 cells were then treated as indicated and imaged under bright field and fluorescence 
microscopy using an Eclipse TS100 microscope and DS-QiMc digital camera (Nikon, Melville, 
NY). Five images were taken per group, along with their corresponding bright field images, and 
the number of ASC specks per visual field per cell were counted. 
IL-1β and TNFα ELISAs 
 ELISAs were conducted according to manufacturer’s protocols (BD Biosciences, San 
Jose, CA). Briefly, 96-well high-binding plates (Corning, Kennebunk, ME) were coated 
overnight at 4˚C with IL-1β or TNFα capture antibody diluted in coating buffer (100mM 
NaHCO3, 33.6mM Na2CO3, pH 9.5) overnight. The following day, plates were washed three 
times and blocked in 10% FBS/PBS for 1 hour at room temperature. The plates were then 
washed three times and standards and samples were added for 2 hours. After an additional three 
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washes, diluted detection antibodies were added to the plates for 1 hour. The plates were again 
washed three times and Streptavidin-HRP was added for 30 minutes. After washing the plates 
four times, substrate solutions A and B (R&D Systems) were mixed at a 1:1 ratio, added to the 
plate, and 2M H2SO4 was added to stop the development of the reaction. Plates were then read 
on a BioTek PowerwaveX (Winooski, VT) instrument at 450nm with a λ correction of 570nm 
using the program Gen5 1.1. 
Cell Death Assay 
 Cell death was assessed via a lactate dehydrogenase (LDH) assay in cell culture 
supernatant using CyTox96 assays, according to manufacturer’s directions (Promega, Madison, 
WI). Briefly, in a 96-well plate (Corning) a standard curve of 100% cell death was created with 
J774 cell lysates and the samples were loaded at a 1:5 dilution in assay buffer at a total volume 
of 50μl. To this, 25μl of substrate mix was added, the plate was incubated in the dark for 30 
minutes, and 25μl of stop solution was added to each well. The plate was then read using a 
BioTek PowerwaveX instrument at 490nm using the program Gen5 1.1. 
Protein Quantification 
 Protein was quantified using a detergent compatible assay (Bio-Rad, Hercules, CA), 
according to manufacturer’s directions. Briefly, working reagent A was prepared by mixing 
Assay Reagent S with Assay Reagent A at a ratio of 1:25. Sample, BSA standard or blank were 
added to a 96-well plate, and mixed with working reagent A at a ratio of 1:5.  To this, 200μl of 
assay reagent B was added and the plates were incubated for 15 minutes on a shaker at room 
temperature. The plates were subsequently read using a BioTek PowerwaveX instrument at 
750nm using the program Gen5 1.1. 
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Chloroform-Methanol Protein Precipitation from Cell Supernatants 
Supernatants from cells cultured in 6-well plates in serum free media were divided into 
Eppendorf tubes with 500μl of media per tube.  An equal volume of methanol to supernatant 
(500μl) and ¼ volume of chloroform (125μl) was added, and the samples were vortexed for 20 
seconds. Samples were then spun down at 20,000g for 10 minutes at room temperature and the 
upper phase of the mixture was removed, keeping the intermediate protein phase intact. To this, 
500μl of methanol was added, the samples were vortexed for 20 seconds, and spun down at 
20,000g for 5 minutes at room temperature. The liquid phase was removed and the pellet was 
dried at 55˚C for 1-5 minutes. The pellet was then resuspended in 15μl of PBS, duplicate 
samples were pooled together and protein concentrations were measured by a detergent 
compatible protein assay before being mixed with 4x Lamelli sample buffer containing β-ME, 
and vortexed an additional 20 seconds. 
Western Blots 
 Cell culture supernatants were based on equivalent volumes, whereas cell lysate samples 
were normalized to total protein, and prepared by diluting 1:4 in 4x β-ME sample buffer, heating 
at 100˚C for 5 minutes, vortexing for 20 seconds, and brief centrifugation to remove the 
condensation from the tubes. Samples were then loaded onto gels, run in 1x TGS running buffer, 
and transferred to nitrocellulose (for probing with ASC, caspase-1 and phosphotyrosine 
antibodies) or PVDF (for probing with IL-1β antibody) membranes. Blots were blocked in 5% 
milk/TBST (IL-1β, ASC and β-actin), 0.5% milk/TBST (caspase-1) or 3% BSA/TBST 
(phosphotyrosine) for 2 hours at room temperature, and placed in primary antibody overnight at 
4˚C. Blots were then washed three times in TBST for 10 minutes and placed in biotin-conjugated 
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Figure 1. IL-1β (A) and TNFα (B) ELISAs on supernatants 
from J774 cells treated as indicated with LPS, ethanol, and 
ATP. *<0.0001 by one-way ANOVA relative to the LPS+ATP 
treated group. EtOH = ethanol. 
secondary antibody for 2 hours at room temperature. The blots were again washed and incubated 
in ECL reagent (Thermo Scientific) for 5 minutes before exposing to X-ray film and developing. 
Ponceau Staining 
 J774 cells were treated as indicated and lysates and supernantants were prepared as 
previously described and separated by SDS-PAGE. Proteins within the gel were transferred onto 
nitrocellulose and washed with TBS for 5 minutes. The membrane was then placed in ponceau 
stain (0.1% ponceau S (Sigma-Aldrich) in 5% acetic acid) for 5 minutes, and washed with water 
tree times for 5 minutes each. 
Statistical Calculations 
 All experiments were repeated at least twice and representative results are presented. 
Results were analyzed by two-tailed unpaired t test, one-way ANOVA or two-way ANOVA and 
Bonferroni post hoc test using GraphPad Prism 5 for Windows (GraphPad). A p value <0.05 or 
<0.0001was considered statistically significant. 
 
Results 
Ethanol Can Inhibit ATP-Induced 
IL-1β Secretion 
 The combination of priming 
macrophages with the TLR4 
agonist lipopolysaccharide (LPS) 
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and stimulating with the DAMP ATP is a well characterized method of inducing NLRP3 
inflammasome activation (9).  In order to test whether ethanol is capable of inhibiting IL-1β 
secretion subsequent to NLRP3 inflammasome stimulation, J774 cells were primed with LPS for 
3 hours, pre-treated with ethanol for an additional 3 hours, and stimulated with ATP for 4 hours. 
Ethanol significantly and dose dependently inhibited the secretion of IL-1β relative to cells 
treated with LPS and ATP alone (Figure 1A). In addition, TNFα production was unaffected by 
ethanol, suggesting that NF-κB activation and priming of the inflammasome were not influenced 
by the alcohol at this time point (Figure 1B). Therefore, it is likely that ethanol acts on either 
signal 2 (activation) or signal 3 (secretion) to prevent IL-1β secretion from the NLRP3 
inflammasome. 
Ethanol Exposure does not Promote Cell Death 
 To ensure that the doses of ethanol 
used in these experiments would not be 
toxic to our cell line, an LDH assay was run 
on the supernatants of LPS primed J774 
cells pre-treated with ethanol for up to three 
hours and stimulated with ATP. Ethanol 
administration to J774 cells alone for 7 
hours and for 4-7 hours during 
inflammasome activation did not induce 
measureable cell death by LDH assay (Figure 2). These results validated that the maximum dose 
of ethanol used in our studies (3% v/v) did not induce a loss of cellular viability. Therefore, it 
Figure 2. An LDH assay on the supernatants of J774 
cells treated with LPS, ATP, and ethanol as indicated 




was determined that doses of ethanol at and below 3% were acceptable for use in these 
experiments. 
Ethanol Does Not Interfere with the IL-1β or TNFα ELISAs 
 It was feasible that the presence of ethanol in the supernatants could interrupt protein 
structure and inhibit an ELISA’s ability to detect IL-1β. To rule this out, three standard curves of 
recombinant mature IL-1β were run on an ELISA in the presence of 0, 1.5, and 3% ethanol.  
Treatment with 3% ethanol was capable of interfering with the detection of IL-1β, generating 
calculated IL-1β levels that were up to 28% below the expected value (Figure 3A). However, 
this is significantly less than the 92% decrease in IL-1β secretion observed from J774 cells 
primed with LPS and pre-treated with 3% ethanol before stimulation with ATP when compared 
to cells treated with LPS and ATP alone (Figure 3B). These results indicate that the decrease in 
IL-1β that we measure through ELISAs is primarily the result of a reduction in the amount of 
secreted IL-1β protein. 
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Figure 3. An IL-1β ELISA of cytokine standards treated with 0, 1.5, and 3% ethanol to 
measure the alcohol’s ability to interfere with the assay (A). An IL-1β ELISA on supernatants 
from J774 cells unstimulated, treated with LPS (10h), with LPS (6h) and ATP (4h), or 
pretreated with ethanol (3h) before ATP addition (B). A TNFα ELISA of cytokine standards 
treated with 0, 1.5, and 3% ethanol (C). EtOH = ethanol. 
 
C 
 Since ethanol did interfere slightly with the IL-1β ELISA’s ability to detect its target 
protein we diluted TNFα standards in 0, 1.5, and 3% ethanol to determine its capacity to exert a 
similar effect on the TNFα ELISA. Ethanol showed no ability to alter the performance of the 
TNFα ELISAs (Figure 3C), which matches our results showing no change in TNFα secretion 
from groups treated with the alcohol.  
Ethanol Can Inhibit NLRP3 Inflammasome Activation by a Variety of Agonists 
To evaluate upon which pathways leading to NLRP3 inflammasome activation ethanol 
can act, LPS primed J774 cells were treated with ethanol prior to stimulation with several 
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Figure 4. IL-1β and TNFα ELISAs on supernatants from J774 cells treated as indicated with LPS, ethanol, 
and nigericin (A), alum (B), or apoSAA (C) to determine ethanol’s capacity to inhibit infalmmasome 
formation in response to different types of agonists. *<0.0001 by one-way ANOVA relative to the 
LPS+Nigericin (A) +Alum (B) or + apoSAA (C) treated groups. EtOH = ethanol. 
additional NLRP3 agonists (nigericin, alum, and apoSAA), which act though different upstream 
mechanisms distinct from those utilized by ATP (P2X7 receptor activation) to induce 
16 
 
inflammasome stimulation. Ethanol significantly and dose dependently inhibited the secretion of 
IL-1β from cells stimulated with each of these three agonists, while having no substantial impact 
on TNFα production (Figure 4). Since ethanol is capable of preventing IL-1β secretion in 
response to each agonist without altering TNFα production, this implies that ethanol’s actions are 
likely on downstream events in NLRP3 inflammasome formation, where the three pathways 
converge. 
 Kinetics of Ethanol Inhibition 
 Elucida










mechanisms through which this chemical might be acting. To observe the kinetics of ethanol 
inhibition, ethanol (3%) was administered to LPS primed cells 2 and 1 hours before and 
simultaneously with ATP stimulation, as well as at several times points following ATP addition. 
Ethanol treatment at each time point before ATP addition and up to 15 minutes after stimulation 
was found to inhibit NLRP3 inflammasome activation, and consistent with previous 
Figure 5. IL-1β (A) and TNFα (B) ELISAs on supernatants from J774 cells unstimulated, primed 
with LPS, treated with LPS and ATP, or treated with LPS, ATP, and ethanol at indicated time 
points pre and post ATP addition to determine the kinetics of ethanol’s inhibition of the NLRP3 







Figure 6. Western blots on J774 cell lysates treated as indicated and probed for 
IL-1β and β-actin (A), and supernatants from the same experiment probed for IL-
1β (B). EtOH = ethanol. 
 
experiments, ethanol treatment had no impact on macrophage priming and TNFα production 
(Figure 5). These results indicate that the effects of ethanol are immediate and unlikely to be due 
to slower cell signaling processes such as alterations in gene expression.  
Ethanol Prevents the Cleavage of Pro-IL-1β into its Mature Form 
 Since the decrease in IL-1β production observed by ELISA could be due to retention of 
cleaved IL-1β within the cell rather than inhibition of caspase-1 and inflammasome action, 
western blots were 
performed to 
determine whether 
mature IL-1β could be 
found in the lysates or 
the supernatants of 
primed, ethanol treated 
macrophages 
stimulated with ATP. 
Consistent with an 
absence of caspase-1 
enzymatic activity, there was no cleaved IL-1β visible in either the cell lysates or supernatants of 
ethanol treated cells (Figure 6). There was, however, abundant 17kDa mature and alternatively 
cleaved 28kDa IL-1β in cells treated with LPS and ATP alone. From LPS and ATP treated cells 
both with and without ethanol administration, pro-IL-1β was detected in the supernatants. This 
could be due to ATP induced cell death occurring at too low a level to be identified by LDH 
assay and subsequent leakage of pro-IL-1β from damaged cell membranes. Despite some 
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secretion of pro-IL-1β, there was still a greater concentration of pro-IL-1β retained in the lysates 
of cells treated with ethanol verses those treated only with LPS and ATP, likely representing the 
pool of pro-IL-1β that was not converted to mature IL-1β and secreted. 
Treatment with Ethanol Prevents ASC and 
Caspase-1 Secretion 
 The activity of functional inflammasomes 
results in the secretion of not only IL-1β and IL-18, 
but also other inflammasome components, 
including NLRP3, ASC, and caspase-1. To further 
validate that ethanol inhibits inflammasome 
activation, western blots of the lysates and 
supernatants of J774 cells were probed with anti-
ASC or anti-caspase-1 antibodies. While 
constitutively expressed ASC was detected in the 
lysates of every group (Figure 7A), there was 
significantly less ASC (Figure 7B) and no mature 
caspase-1 (Figure 7C) identified in the 
supernatants of cells pre-treated with ethanol. 
However, ASC and caspase-1 were detected in the 
supernatants of LPS and ATP treated cells, 
indicating successful inflammasome stimulation with this protocol. Similar to pro-IL-1β, pro-
caspase-1 was detected in the supernatants of both groups treated with ATP.  
Figure 7. Western blots of lysates (A) and 
supernatants (B and C) from J774 cells treated 
with LPS (37ng/ml), ATP (5mM) and ethanol 
(3%) as indicated and probed for ASC (A and 



























Figure 8. A Ponceau stain lysates and 
supernatants from J774 cells treated with 
LPS (37ng/ml), ATP (5mM) and ethanol 





















 Ethanol Cannot Reverse ATP-Induced Protein 
Secretion 
 J774 cells were treated as indicated and a 
Ponceau stain was performed on both cell lysates and 
precipitated supernatants (Figure 8). Even amounts of 
protein were detected in the lysates of each group; 
however, secreted proteins could only be detected in 
those treated with ATP. There was no discernible 
inhibition of general protein secretion with the 
addition of ethanol, indicating that the absent mature 
IL-1β, caspase-1, and ASC secretion observed after 
treatment with ethanol is due to direct inhibition of 
the NLRP3 inflammasome.  
Ethanol Displays Incomplete 
Inhibition of IL-1β Secretion 
from ASC Independent 
Inflammasomes 
 To determine whether 
ethanol’s inhibition might be 
ASC dependent, J774 cells 
were treated with flagella, 
which contains the NLRC4 
Figure 9. IL-1β  and TNFα  ELISAs from supernatants of J774 cells 
treated with the NLRC4 agonist, flagella (A) or the NLRP1b agonist 
anthrax lethal toxin (B) with or without ethanol. *<0.0001 by one-
way ANOVA relative to the flagella or LPS+LT treated groups. 
EtOH = ethanol. 
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agonist flagellin.  As flagella acts as both a signal 1 and 2 agonist, the cells were treated with 
ethanol (1.5-3%) at the same time as flagella (10μg/ml) to ensure that it would have sufficient 
time to block signal 2 at the expense of potentially also inhibiting inflammasome priming. In 
contrast to NLRP3 agonists, ethanol was only able to partially inhibit the NLRC4 inflammasome 
and IL-1β secretion (Figure 9A). In addition, LPS primed J774 cells were treated with the 
NLRP1b agonist anthrax lethal toxin (LT), a combination of anthrax lethal factor (LF 1μg/ml) 
and protective antigen (PA 1μg/ml), both with and without ethanol. Similar to NRLC4 
inflammasomes, NLRP1b inflammasome stimulation could not be inhibited by the 
administration of ethanol (Figure 9B). As NLRC4 and NLRP1b inflammasome activation is 
enhanced by, but not dependent on, the adaptor protein ASC, these results could support ASC 
speck formation as a target of ethanol’s inhibition.  
Ethanol Treatment Inhibits ASC Speck Formation 
 Since ASC speck formation is a point of 
convergence for all NLRP3 inflammasome activators and 
we have shown that ethanol cannot completely inhibit IL-
1β secretion from the partially ASC-independent NLRC4 
inflammasome, we tested the ability of ethanol to prevent 
the formation of ASC specks. THP-1 cells stably 
transfected to express a fusion protein of ASC and GFP 
were treated with nothing, LPS, LPS and ATP, or LPS, 
ethanol and ATP and were observed by fluorescence 
microscopy to visualize the generation of ASC specks. 
Figure 10. ASC-EGFP transfected 
THP-1 cells treated with LPS 
(100ng/ml), ethanol (3%), and ATP 
(5mM) as indicated and imaged 
using using bright field and 
fluorescence microscopy for total 
cell counts and speck formation. 
*<0.05 by one-way ANOVA relative 
to the control group. 
4 Hours 1 Hour 
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Five images were taken per group along with corresponding bright field images to calculate the 
number of specks formed per total number of cells per image. EGFP stably transfected THP-1 
cells were used as a negative control and consistently demonstrated no visible speck formation 
under fluorescence microscopy in response to any of the four treatments. Both untreated and LPS 
primed ASC-EGFP THP-1 cells exhibited low levels of speck formation (Figure 10). 
Stimulation with ATP significantly increased the number of ASC specks present per cell per 
visual field, and this increase was nearly completely ameliorated by the administration of ethanol 
alongside ATP. 
Ethanol Decreases Global Tyrosine 
Phosphorylation 
Ethanol has been reported to activate 
tyrosine phosphatases, and the phosphorylation of 
ASC at Y144 (mouse) and Y146 (human) has been 
proven to be vital for ASC speck and 
inflammasome formation to occur (14). To test 
whether ethanol has global effects on tyrosine 
phosphorylation in macrophages, we treated J774 
cells as indicated and performed western blots on 
the lysates, probing for phosphotyrosine. As 
anticipated, ethanol treatment greatly reduced 
tyrosine phosphorylation relative to controls, while 
having no effect on β-actin levels (Figure 11). 
 
Figure 11. Western blots of lysates from 
J774 cells treated with LPS (37ng/ml), ATP 
(5mM), and ethanol (3%) as indicated and 
probed for phosphotyrosine and β-actin. 
EtOH = ethanol. 
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There was an unexpected decrease in tyrosine phosphorylation in LPS and ATP treated cells, 
possibly due to loss of select proteins secreted during inflammasome activation. 
Phosphatase Blockade Ameliorates Ethanol’s Inhibition of IL-1β Secretion 
 To evaluate whether ethanol’s NLRP3 inhibitory activity might be a result of increased 
tyrosine phosphatase activity, J774 cells were pre-treated with sodium orthovanadate (100-
1000μM) 30 minutes prior to ethanol and ATP stimulation. All doses of sodium orthovanadate 
used reversed the effects of ethanol’s inhibition (Figure 12). To ensure that any increases in IL-
1β detected by ELISA would not be due to cell death and leakage of pro-IL-1β into the 
supernatants, cells were primed with LPS and treated with sodium orthovanadate with the same 
doses and for the same period of time as those receiving ethanol and ATP. In these groups, no 
Figure 12. IL-1β (A) and TNFα (B) ELISAs on the supernatants from J774 cells untreated, primed with LPS, 
stimulated with LPS and ATP, LPS, ATP, and ethanol, and LPS, ATP, and ethanol pre-treated with Na3VO4, to 
block the activity of phosphatases globally. *<0.0001 by one-way ANOVA relative to the LPS+ATP treated 
group. EtOH = ethanol, Na3VO4 = sodium orthovanadate. 
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Figure 13. IL-1β and TNFα ELISAs on supernatants from J774 cells treated as indicated with 
LPS, ATP, ethanol, and the GABAA channel blocker picrotoxin (A), or from cells treated with the 
GABAA channel agonist muscimol prior to priming with LPS or stimulation with ATP (B). 
*<0.0001 by one-way ANOVA relative to the LPS+ATP+EtOH 1.2% or 3% treated groups. EtOH 
= ethanol. 
IL-1β was detected in the supernatants, indicating that sodium orthovanadate’s reversal of 
ethanol’s inhibition was due to true restoration of IL-1β secretion. 
GABAA Receptors Are Not Necessary or Sufficient for the Inhibitory Effects of Ethanol 
 Ethanol is a known agonist for GABAA receptors, which when activated function as a 
chloride specific ion channel (34). GABAA receptors have been found on macrophages and their 
activation has been shown to have anti-inflammatory effects (35). To test whether activation of 
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GABAA receptors on J774 cells is responsible for ethanol’s rapid immunosuppressive effects, 
groups were treated with the GABAA receptor antagonist picrotoxin (100 or 500mM) 
immediately before the addition of ethanol (1.2% or 3%) and ATP to prevent channel opening. 
Blockade of GABAA receptors had no impact on the inhibitory effects of ethanol either at its half 
maximal inhibitory dose of 1.2% or is fully inhibitory concentration of 3% (Figure 13A). This 
indicates that GABAA receptors are not necessary for ethanol to inhibit NLRP3 inflammasome 
activation. To test whether GABAA receptor activation was sufficient for NLRP3 inflammasome 
blockade, J774 cells were given the GABAA receptor agonist muscimol (100-1000μM), directly 
before LPS priming or ATP stimulation. Muscimol was unable to prevent IL-1β and TNFα 
secretion when given before the signal 1 agonist LPS or the signal 2 agonist ATP (Figure 13B). 
From these data, we determined that GABAA receptor activation is unable to inhibit either of the 
two steps needed for NLRP3 inflammasome activation to occur.  
NMDA Receptor Inhibition Is Not Sufficient to Block NLRP3 Activation 
 NMDA receptors 
are ionotropic 
neurotransmitter receptors 
that open to form a non-
specific cation channel and 
are antagonized by ethanol (31). 
Like GABAA receptors, 
they have also been found 
on leukocytes, and in 
microglial cells their activation results in TNFα and IL-1β production (36). To determine 
Figure 14. IL-1β (A) and TNFα (B) ELISAs from supernatants of J774 
cells which were treated with LPS, ATP, ethanol, and the NMDA 
receptor antagonist as indicated. *<0.0001 by one-way ANOVA relative 




Figure 15. IL-1β (A) and TNFα (B) ELISAs on supernatants from J774 cells treated with LPS, ATP, 
methanol, ethanol, 1-propanol, isopropanol, glycerol, lactate, isoamyl alcohol and 2-methylbutane as 
indicated. *<0.0001 by one-way ANOVA relative to the LPS+ATP treated group. 
whether NMDA receptor antagonism could block inflammasome activation, the antagonist 3-(2-
Carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP: 500-3.9μM) was administered to LPS 
primed J774 cells before stimulation with ATP. Antagonism of this neurotransmitter receptor did 
not prevent IL-1β secretion at any dose (Figure 14). Therefore, we concluded that NMDA 
receptor inhibition does not block NLRP3 inflammasome activation and is unlikely to be 
involved in the pathway of ethanol’s inhibition of this system.  
Different Chain Length Alcohols can Inhibit NLRP3 Inflammasome Activation 
To test whether inhibition of the NLRP3 inflammasome is specific to ethanol, we treated 
cells with the hydroxyl group containing organic compounds: methanol, 1-propanol, isopropanol, 
glycerol, lactate, and isoamyl alcohol, which are both shorter and longer in carbon chain length 
than ethanol. We found that when administered to J774 cells these alcohols had inhibitory 
actions on NLRP3 inflammasome stimulation parallel to those of ethanol (Figure 15A). 
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However, 2-methylbutane, the non-alcohol analog of isoamyl alcohol, lacked the ability to 
antagonize IL-1β secretion (Figure 15B). These data indicate that several types of alcohols are 
capable of inhibiting the NLRP3 inflammasome and that this inhibition might be dependent upon 




There has been a long noted association between alcohol abuse and susceptibility to 
opportunistic infections. Alcoholics have globally disturbed immune function, including 
Figure 16. A summary of our proposed mechanism of NLRP3 inflammasome inhibition 
mediated by organic alcohols. 
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decreased macrophage phagocytosis, disrupted T-cell signaling, diminished levels of circulating 
pro-inflammatory cytokines, and paradoxically, symptoms of chronic inflammation (25, 37-39). 
In these studies, we show that in the setting of acute exposure to ethanol macrophages display 
markedly attenuated activation of the NLRP3 inflammasome and production of the pro-
inflammatory cytokine IL-1β, thus providing a potential site of action for ethanol in the complex 
syndrome of alcohol induced immunosuppression. The doses of ethanol used in this experiment 
were high (0.38-3% or 64-512mM). However, considering that concentrations of alcohol in the 
blood, brain, and upper gastrointestinal tract can reach 100, 200, and 3400mM, respectively, 
following binge drinking (17, 40, 41), and that our highest dose of ethanol used did not induce 
measurable cytotoxicity, we feel that our chosen doses have physiologic relevance (Figure 2). 
 We have demonstrated that ethanol is capable of preventing IL-1β secretion after 
sufficient priming with the bacterially derived TLR4 agonist lipopolysaccharide (LPS) without 
impacting TNFα release (Figure 4). TNFα production occurs as a result of NF-κB and step 1 
activation. The lack of a decline in the production of TNFα subsequent to ethanol treatment 
validates that the object of the alcohol’s inhibition in these experiments is likely (directly or 
indirectly) assembly of the NLRP3 inflammasome itself (step 2), or secretion of the leaderless 
protein (step 3).  
The fact that ethanol can prevent IL-1β secretion occurring in response to a variety of 
step 2 agonists implies that its site of action is probably an apical event in NLRP3 inflammasome 
stimulation in which each of the four pathways tested converge (Figure 4). The endogenous 
DAMP, ATP, and the bacterially derived PAMP, nigericin, are both believed to activate the 
NLRP3 inflammsome by inducing K
+
 efflux from the cells. This occurs via activation of the 
P2X7 receptor and the pannexin 1 hemichannel by ATP and through the formation of pores in 
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the plasma membrane by nigericin itself (9, 10). Ethanol does not inhibit the release of cellular 
potassium induced by nigericin (17), so we do not believe this to be a mechanism to explain the 
effects of ethanol on NLRP3 inflammasome activation. Aluminum hydroxide, a particulate 
commonly used as an adjuvant in vaccines, incites inflammasome activation through frustrated 
phagocytosis, lysosomal rupture, and leakage of cathepsins into the cytosol (11). Apo-SAA is a 
recombinant protein containing an amino acid sequence that is a hybrid of the endogenous acute 
phase proteins human SAA1 and 2, and an N-terminal methionine. It is not yet completely 
understood how apo-SAA stimulates the NLRP3 inflammasome, but due to the protein’s ability 
to form amyloid plaques disrupted phagocytosis is a possibility (42, 43). The complete pathway 
for each of these stimuli is still unclear, but all lead to the formation of an ASC speck upon 
inflammasome activation (14). This is one of the first well characterized points of convergence 
between the pathways of all known NLRP3 inflammasome step 2 agonists. 
Also lending credibility to the hypothesis that ethanol inhibits apical events in NLRP3 
inflammasome activation is our finding that the alcohol can reduce IL-1β secretion when given 
up to 15 minutes after stimulation with ATP (Figure 5). This additionally implies that ethanol’s 
effects on macrophages is nearly immediate, making ethanol’s known ability to alter gene 
expression an unlikely candidate for its influence on NLRP3 inflammasome activity. 
Activation of inflammasomes leads to conventionally and alternatively cleaved 17 and 
28kDa mature IL-1β. Consistent with a lack of NLRP3 inflammasome activity, no cleaved IL-1β 
was detected in primed J774 cells given ethanol alongside ATP, despite abundant production 
from those cells given LPS and ATP alone (Figure 6). There was additionally no cleaved IL-1β 
present in the lysates of ethanol treated cells, supporting the hypothesis of inhibition of 
inflammasome activation rather than protein secretion, although it is possible that retained IL-1β 
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might have been degraded before the lysates were collected and therefore went undetected. 
Furthermore, no cleaved caspase-1 or secreted ASC could be identified in the supernatants of 
ethanol treated cells, which are other signs of inflammasome activity (Figure 7). Taken together, 
these results support adequate NLRP3 inflammasome stimulation following 8 hours of priming 
with LPS and 1 hour of stimulation with ATP, which is completely blocked when ethanol is 
administered alongside ATP. This blockade of mature IL-1β, caspase-1, and ASC secretion is 
unlikely to be due to inhibition of protein secretion (step 3) by ethanol, as we have shown by 
Ponceau stain that ethanol treatment does not influence general protein secretion in response to 
ATP (Figure 8). 
In an attempt to test whether ethanol may act by preventing ASC speck formation, 
ethanol was given simultaneously with the addition of the NLRC4 inflammasome agonist 
flagella or the NLRP1b agonist anthrax LT. Unlike its complete inhibition of IL-1β secretion due 
to NLRP3 inflammasome activation, ethanol at our highest administered dose of 3% could only 
partially inhibit IL-1β production subsequent to activation of the NLRC4 inflammasome by 
flagella (Figure 9A) and was incapable of inhibiting NLRP1b reliant IL-1β secretion (Figure 
9B). NLRC4 and NLRP1b inflammasomes are amplified by, but are not dependent on, ASC 
speck formation. Therefore, the partial and absent responses to ethanol in these experiments 
could be due to a lack of a requirement for ASC speck formation by these inflammasomes. If this 
is the case, this would indicate that a main point of action for ethanol is inhibition of the adaptor 
protein’s ability to mediate inflammasome assembly. It should be noted that we used flagella for 
this experiment, while the true NLRC4 agonist is a subunit of flagella, flagellin. It is possible 
that flagella might exert unanticipated effects our macrophages beyond those of the purified 
flagellin subunit, making our results more difficult to interpret. As a more direct method of 
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determining whether ethanol can prevent ASC speck formation, we used ASC-EGFP stably 
transfected THP-1 cells to visualize ASC speck formation in real time. In response to LPS and 
ATP, the quantity of specks visible per cell per visual field rose above baseline and this increase 
was completely prevented by ethanol treatment (Figure 10). Consistent with ethanol’s 
incomplete inhibition of the NLRC4 inflammasome, this indicates that ethanol does act to 
prevent NLRP3 inflammasome activation at the level of ASC speck formation. 
It has recently been shown that phosphorylation at Tyr146 (human) and Tyr144 (mouse) 
of ASC is necessary for speck formation to occur (14). Additionally, treatment of neurons with 
ethanol results in the activation of several tyrosine phosphatases (44, 45). Therefore, we 
measured total levels of tyrosine phosphorylation in the lysates of J774 cells stimulated to 
activate the NLRP3 inflammasome, treated with and without ethanol, to determine whether 
ethanol might decrease tyrosine phosphorylation in macrophages as well. A 3% dose of ethanol 
was capable of markedly decreasing global tyrosine phosphorylation when measured via western 
blot (Figure 11). In addition, pre-treatment with the phosphatase inhibitor sodium orthovanadate 
reversed the ability of ethanol to prevent IL-1β secretion (Figure 12). As proper functioning of 
the NLRP3 inflammasome requires the phosphorylation of ASC at these critical tyrosine residues 
and since the actions of ethanol appear to be phosphatase dependent, it is possible that ethanol 
could work by activating phosphatases, inducing the dephosphorylation of ASC, and preventing 
its aggregation. We did attempt to immunoprecipitate ASC and perform an anti-phosphotyrosine 
western blot to observe whether ethanol treatment can reduce the phosphorylation of ASC. 
However, due to the insolubility of ASC specks, the protein is difficult to immunoprecipitate and 
we did not obtain interpretable results. 
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We next attempted to determine how ethanol first transduces its signal into macrophages. 
The alcohol can serve as an agonist and antagonist to a number of neurotransmitter receptors, 
which leads to many of its effects on cerebral functioning (30, 31). Several of these receptors 
have recently been found to be expressed on leukocytes and their activation can skew immune 
responses towards pro- or anti-inflammatory states. Activation of GABAA receptors results in 
decreased production of TNFα, IL-1β, and several other pro-inflammatory cytokines from 
macrophages and T-cells, and treatment of mice with GABAA agonists can improve disease 
status in models of multiple sclerosis and asthma (35, 46). In contrast, stimulation of NMDA 
receptors on microglial cells leads to increases in TNFα and IL-1β secretion (36). Ethanol is both 
an agonist of GABAA receptors and an antagonist of NMDA receptors, making each of these 
proteins feasible targets for the alcohol in NLRP3 inflammasome suppression (30, 31). However, 
our results show that neither the stimulation of GABAA nor the antagonism of NMDA receptors 
is sufficient to inhibit IL-1β secretion and mimic the effects of ethanol (Figures 13 and 14). 
These receptors were attractive targets since they are expressed on macrophages, have been 
shown to alter IL-1β production, and are modified by ethanol. However, there are many other 
receptors on macrophages, not already associated with inflammasome activity, with which 
ethanol may interact (47, 48). It is possible that one of these may be the relevant target of the 
alcohol to prevent inflammasome activation. It is equally likely that ethanol might diffuse across 
the plasma membrane and directly modify cytosolic proteins. Additional techniques beyond the 
scope of this thesis work will be required to provide meaningful insight into these interesting 
possibilities. 
Alcohols of similar chain lengths can exert comparable effects on proteins (28). Here we 
show that several different organic compounds containing alcohol residues can mimic ethanol’s 
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antagonism of the NLRP3 inflammasome (Figure 15). The parallel actions of these alcohols on 
the inflammasome could be due to similar chemical properties, or the fact that many of the 
binding pockets for ethanol within proteins can interact with similarly sized alcohols. Notably, 
we show here that isoamyl alcohol possesses the ability to inhibit IL-1β secretion subsequent to 
NLRP3 inflammasome stimulation while 2-methylbutane, containing the same carbon backbone 
but lacking an alcohol group, does not (Figure 15). These findings indicate that the hydroxyl 
group of a chemical is important in exerting an inhibitory effect on this system. 
While the knowledge that the presence of an alcohol group on a chemical plays a key role 
in inhibiting NLRP3 inflammasome formation could provide significant information about the 
mechanism of ethanol’s action within cells, it also might prove useful in identifying other 
relevant molecules capable of inhibiting this vital PRR. The ketone metabolite β-
hydroxybutyrate (BHB), a four carbon compound containing both a hydroxyl and carboxyl 
group, is capable of specifically inhibiting the NLRP3 inflammasome by preventing potassium 
efflux and ASC oligomerization (49). This compound is produced endogenously during fasting 
and exercise to support ATP production during states of energy deficit, providing a possible 
explanation for the reduction in inflammation observed with prolonged fasting (49). Similar to 
our results obtained from isoamyl alcohol and 2-methylbutane, BHB’s immunosuppressive 
activity on the NLRP3 inflammasome is absent in its alcohol free analog, butyrate (49). As we 
have shown that similarly sized short-chain alcohols exert comparable inhibition on the NLRP3 
inflammasome, it is possible that all of these small molecules are acting through the same 
pathway. Therefore, it is probable that still more endogenous metabolites containing hydroxyl 
groups could possess inhibitory activity against the NLRP3 inflammasome. Identifying these 
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compounds could afford significant insight into the mechanisms of immune homeostasis during 
both diseased and resting states. 
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